AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02891564 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Mobile 3D video game
Description: expectancy-matched control game
Study NCT03787108 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance spectroscopy measurement
Description: Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
Study NCT04605523 — intervention group
Intervention type: PROCEDURE
Intervention: blood withdrawal
Description: Additional blood sample will be taken within blood collection as part of standard care
Study NCT02036528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Topical Gel
Study NCT02036528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Study NCT02036528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Study NCT02036528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Study NCT02036528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study NCT00562692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide 4 hour infusion
Study NCT00562692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study NCT01526915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone curettage + PRF
Description: Bone curettage and PRF insertion
Study NCT01526915 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone curettage alone
Description: Bone curettage without PRF insertion
Study NCT00164203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
Study NCT00164203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based CBT
Description: 12 sessions, weekly
Study NCT00164203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: activity control condition
Description: weekly games \& activities x 12 weeks
Study NCT01682941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arm I Soy Bread
Description: On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
Study NCT01682941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm II Soy-Almond Bread
Description: On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
Study NCT00006031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle localized breast biopsy with specimen x-ray
Study NCT00006031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low dose radioactive seed followed by surgery and mammogram
Description: either iodine I 125 or palladium Pd 103
Study NCT02116491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Sputum Suctioning System
Description: All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
Study NCT02076191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
Study NCT02076191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
Study NCT02479412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 58 µg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study NCT02479412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo once daily
Description: Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study NCT02479412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Inhalation as needed
Study NCT03006250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
Study NCT03006250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
Study NCT01311492 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Lifestyle Program
Description: The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes.
Study NCT01311492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Description: The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
Study NCT01571362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02
Description: 20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
Study NCT01571362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo, divided into symmetric doses and administered twice daily
Study NCT02529774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
Description: Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1
Study NCT02414425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectoscopy
Description: A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
Study NCT02414425 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rectoscopy
Description: A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
Study NCT02414425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Description: Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
Study NCT02414425 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Anorectal manometry
Description: Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
Study NCT02414425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A or physiologic serum injection
Description: Botulinum toxin A or physiologic serum injection is performed during rectoscopy
Study NCT02414425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin A or physiologic serum injection
Description: Botulinum toxin A or physiologic serum injection is performed during rectoscopy
Study NCT03392376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Injection
Description: ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
Study NCT03392376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0,9%)
Description: ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
Study NCT03862625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a modular adaptive seating system
Study NCT03862625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise program for scoliosis
Study NCT03862625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercise program for scoliosis
Study NCT02685956 — intervention group
Intervention type: DEVICE
Intervention: Vela Sentosa SA HSV1/2 Qualitative PCR Test
Description: medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
Study NCT06182007 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation (Advanced Life Support) according to current guidelines
Study NCT00642564 — intervention group
Intervention type: OTHER
Intervention: Observational study in Epileptic Patients
Description: Observation study in Epileptic Patients with Migraine and Headache
Study NCT03489668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: metformin administration 1500mg per day
Study NCT03775148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
Study NCT01860482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Newrabell® Tablet 10mg
Study NCT02691806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental protocol
Description: first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.~second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors.
Study NCT01321112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conversion from CNI to MMF
Description: After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
Study NCT01015612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System
Description: The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
Study NCT01047059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib, Bevacizumab
Description: Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.
Study NCT01047059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-D-glucose
Description: Tracer for PET imaging
Study NCT01047059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-L-thymidine
Description: FLT-PET tracer for imaging
Study NCT01047059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-DPTA
Description: Contrast agent for DCE-MRI imaging
Study NCT03529513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Medibio Depression Diagnostic Aid
Description: The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.
Study NCT02529774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
Description: Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1
Study NCT00924885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swemed Follicle Aspiration Set Reduced Single Lumen
Description: Thin tip to penetrate the tissue
Study NCT00924885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swemed Follicle Aspiration Set Single Lumen (1.4 mm)
Description: Standard (1.4 mm) needle to penetrate the tissue
Study NCT01348451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical implantation
Description: human spinal cord stem cell implantation in ALS patients
Study NCT02161744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSCs administration
Description: 100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
Study NCT03507166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2 mg/kg IV every 2 weeks
Study NCT02777151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3470-3471-3479
Study NCT03433118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture administered by specially-trained therapeutic radiographers
Study NCT00410852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-assisted IV insulin infusion protocol (algorithm A)
Description: Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
Study NCT00410852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leuven Strict glycemic control protocol (Algorithm B)
Description: Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
Study NCT00410852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Intermittent Insulin Protocol (Algorithm C)
Description: Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
Study NCT00945152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)
Description: Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
Study NCT00945152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, complex gel formulation without Vancomycin
Description: Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
Study NCT01838161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part II
Description: Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
Study NCT01838161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part III
Description: •video educational
Study NCT01838161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Part I
Description: Parental Interviews
Study NCT02117479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets to be administered by mouth twice daily (BID)
Study NCT02117479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5 mg tablets to be administered by mouth twice daily (BID)
Study NCT02117479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 150 and 500 mg tablets to be administered by mouth twice daily (BID)
Study NCT02117479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 150 and 500 mg tablets to be administered by mouth twice daily (BID)
Study NCT02348619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110
Study NCT02818478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reporting of patient reported outcome measures
Description: Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
Study NCT03990389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot Intervention
Description: a chatbot will be used to monitor depression severity
Study NCT02667496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim GZ402664
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02667496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02667496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F18
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT02667496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Florbetapir F18
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT03330028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg by vein approximately 60 minutes before Paclitaxel.
Study NCT03330028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg by vein approximately 60 minutes before Paclitaxel.
Study NCT03330028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 20 mg by vein approximately 60 minutes before Paclitaxel.
Study NCT03330028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
Study NCT03330028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
Study NCT03330028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2.